Trial Profile
A Randomized, Observer-blind, Active Comparator-controlled, Multicenter, Phase 3 Study to Assess the Efficacy, Safety, and Immunogenicity of a Plant-derived Quadrivalent VLP Influenza Vaccine in Adults 65 Years of Age and Older
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Jun 2023
Price :
$35
*
At a glance
- Drugs MT-2271 (Primary) ; GSK 2321138A
- Indications Influenza virus infections
- Focus Registrational; Therapeutic Use
- Sponsors Medicago
- 13 Oct 2020 Results assessing efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus like particle influenza vaccine published in the THE LANCET
- 28 Apr 2020 Primary endpoint has been met. (Occurrence of protocol-defined Influenza-Like Illnesses (ILI) cause by any influenza viral type/subtype)
- 28 Apr 2020 Results published in Mitsubishi Tanabe Pharma Corporation media release.